Iterum Therapeutics plc - Ordinary Share (ITRM): Price and Financial Metrics
GET POWR RATINGS... FREE!
ITRM Stock Price Chart Interactive Chart >
ITRM Price/Volume Stats
| Current price | $1.11 | 52-week high | $7.05 |
| Prev. close | $1.08 | 52-week low | $0.60 |
| Day low | $1.09 | Volume | 112,308 |
| Day high | $1.17 | Avg. volume | 86,356 |
| 50-day MA | $1.20 | Dividend yield | N/A |
| 200-day MA | $2.05 | Market Cap | 13.52M |
Iterum Therapeutics plc - Ordinary Share (ITRM) Company Bio
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is based in Dublin, Ireland.
Latest ITRM News From Around the Web
Below are the latest news stories about ITERUM THERAPEUTICS PLC that investors may wish to consider to help them evaluate ITRM as an investment opportunity.
Iterum Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results--Registration Trial for uUTI Ongoing and On Track----Cash Runway until Mid-2024-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, March 16, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the fourth quarter |
Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023DUBLIN, Ireland and CHICAGO, March 09, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its fourth quarter and fully year 2022 financial results before the open of the U.S. financial markets on Thursday, March 16, 2023. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the week with an overview of the biggest pre-market stock movers traders need to know about for Monday! |
Iterum Therapeutics Reports Employment Inducement GrantDUBLIN, Ireland and CHICAGO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum Therapeutics”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has granted a non-statutory share option to purchase an aggregate of 2,500 ordinary shares of Iterum Therapeutics as an inducement to a newly hir |
Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral SulopenemDUBLIN, Ireland and CHICAGO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the United States Patent and Trademark Office (“USPTO”) has issued Iterum a Notice of Allowance for U.S. patent application number 16/372,075 en |
ITRM Price Returns
| 1-mo | -11.20% |
| 3-mo | 20.65% |
| 6-mo | -39.01% |
| 1-year | -82.38% |
| 3-year | -95.89% |
| 5-year | N/A |
| YTD | 32.14% |
| 2022 | -85.71% |
| 2021 | -60.38% |
| 2020 | -78.02% |
| 2019 | -10.18% |
| 2018 | N/A |
Continue Researching ITRM
Want to see what other sources are saying about Iterum Therapeutics plc's financials and stock price? Try the links below:Iterum Therapeutics plc (ITRM) Stock Price | Nasdaq
Iterum Therapeutics plc (ITRM) Stock Quote, History and News - Yahoo Finance
Iterum Therapeutics plc (ITRM) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...